Insider transactions

Pablo J Cagnoni

CIK 1205703 · President, Global Head of R&D · last filed 2026-10-19

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$21.87M
Companies
7
Total Filings
61
Lifetime Open-Market Net
-$17.46M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

INCY price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
ONYX PHARMACEUTICALS, INC.
249 E. GRAND AVE.
SOUTH SAN FRANCISCO, CA 94080
Related Filers
INCYTE CORP — 28 joint filings, latest 2026-08-20
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
INCY President, Global Head of R&D 185,842 $115.71 $21.50M -$15.71M 23 2026-10-19
Fusion Pharmaceuticals Inc. (FUSN) Delisted Director — $21.55 — $0 5 2024-06-04
Rubius Therapeutics, Inc. (RUBY) Delisted CEO and President 66,082 $0.08 $5.5K $50.6K 8 2023-02-01
CRSP Director 7,500 $49.39 $370.4K -$1.73M 6 2019-11-21
CRISPR Therapeutics AG (PZRX) Delisted Director — — — $0 2 2017-06-02
ONYX PHARMACEUTICALS INC (ONXX) Delisted EVP, Global R&D and Tech Ops 16,257 — — $0 1 2013-03-13
ALLOS THERAPEUTICS INC (ALTH) Delisted Sr. VP, Chief Medical Officer 25,200 — — -$73.3K 6 2009-10-02

Recent Filings · Page 5 of 7

61 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-06-30 Fusion Pharmaceuticals Inc. (FUSN) Delisted Grant (A) — $0 EDGAR
2020-04-15 Rubius Therapeutics, Inc. (RUBY) Delisted Buy (P) +21,000 $98.7K EDGAR
2020-02-03 Rubius Therapeutics, Inc. (RUBY) Delisted Grant (A) — $0 EDGAR
2019-11-21 CRSP Mixed — -$423.1K EDGAR
2019-11-13 CRSP Mixed — -$370.6K EDGAR
2019-11-01 CRSP Mixed — -$348.1K EDGAR
2019-06-13 CRSP Grant (A) — $0 EDGAR
2019-02-04 Rubius Therapeutics, Inc. (RUBY) Delisted Grant (A) — $0 EDGAR
2018-11-01 Rubius Therapeutics, Inc. (RUBY) Delisted Grant (A) — $0 EDGAR
2018-07-05 CRSP Mixed — -$423.1K EDGAR
Showing 41–50 of 61
Page 5 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.